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CC BY-NC-ND license (http://creativeBackground: Urinary tract infections (UTIs) in children with vesicoureteral reflux (VUR) are
often caused by uropathogens with a high rate of drug resistance and are associated with a
high rate of recurrence with a single pathogen. In this study, we evaluated the incidence of
recurrent UTI and the drug resistance pattern of Escherichia coli in children with VUR. We also
evaluated whether combination therapy comprising fosomycin plus one other antimicrobial
agent is effective for treatment of recurrent UTIs.
Methods: We retrospectively reviewed the medical records of all children with VUR who devel-
oped at least one episode of UTI during the period January 1, 2003 to December 31, 2013 at a
single medical center. The effectiveness of fosfomycin plus amikicin for Enterobacteriaceae or
ceftazidime for Pseudomonas aeruginosa infections was prospectively studied in six children
with recurrent relapsing UTIs.
Results: The study population comprised 129 children (age range, from 1month to 15 years;
mean  standard deviation, 2.37  2.91 years) with VUR who developed at least one UTI during
the 10-year study period; 68 (52.7%) had recurrent UTIs. The presence of an underlying urinary
tract anomaly was predictive of recurrence (pZ 0.028). The rates of susceptibility of E. coli toInfection, Department of Pediatrics, Taichung Veterans General Hospital, Number 1650 Taiwan
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718 T.-H. Wu et al.cefazolin (p < 0.001) and cefotaxime (p < 0.001) were significantly lower in patients with
recurrent UTIs. Combination therapy with fosfomycin plus amikacin or ceftazidime was shown
to be an effective therapeutic option for recurrent UTIs due to a single uropathogen.
Conclusion: The rates of susceptibility of E. coli to commonly used antimicrobials were signif-
icantly lower in children who developed more than one episode of UTI. The empiric choice of
cefazolin or cefotaxime was usually ineffective. Administration of fosfomycin plus amikacin or
ceftazidime was an effective therapeutic and preventive strategy in children with VUR and
recurrent relapsing UTI.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Urinary tract infections (UTIs) are one of the most common
bacterial diseases in children, with a prevalence rate of 7.0%
among febrile infants.1 RecurrentUTI is amajor causeof renal
scarring,which can causehypertension, chronic renal failure,
and end-stage renal disease.2,3 Vesicoureteral reflux (VUR) is
diagnosed in 18e40% of children who are investigated for a
first episode of UTI. These children are at an increased risk of
developing recurrent urinary tract and kidney infections,
which, over time, can result in renal damage.2,3 Risk factors
of recurrent UTI in children with VUR include high reflux
grade, delayed contrast passage on voiding cystourethro-
grams, bilateral VUR, and age < 1 year.3e5
Preventive strategies to reduce the risk of acute infec-
tion and renal injury in children with VUR include the
administration of prophylactic antibiotics, endoscopic in-
jection of dextranomer hyaluronic acid, antireflux surgery,
maintenance of good perianal hygiene, and adequate hy-
dration.6 However, breakthrough infections due to drug-
resistant uropathogens sometimes occur, leading to signif-
icant morbidity.
Management of recurrent UTIs in children with VUR is
difficult. Our hypothesis is that multiple factors may lead to
treatment failure in patients with recurrent UTI, including
drug-resistant uropathogens, the mechanism and duration
of antibiotics, surgical damage, and biofilm formation. The
aims of this study were to evaluate the incidence of
recurrent UTI among children with VUR, to evaluate the
incidence of drug resistance among Escherichia coli isolates
from children with recurrent UTI, and to initiate a pilot
study to evaluate the therapeutic effectiveness of fosfo-
mycin for preventing recurrent UTI.Methods
We retrospectively enrolled all children who were treated
for a first episode of UTI and who subsequently received a
diagnosis of VUR at the Taichung Veterans General Hospital,
a 1200-bed tertiary hospital in central Taiwan, during the
period from January 1, 2003 to December 31, 2013. Risk
factors for recurrence, causative uropathogens, and anti-
microbial susceptibility test results were obtained from the
medical records.
Children with VUR were separated into a recurrent UTI
group or a nonrecurrent UTI group. Clinical parameters forstatistical analysis included gender, age, grade of VUR, and
additional urinary tract anomalies. The degree of reflux on
voiding cystourethrography was determined according to
the International Reflux Study classification.7 Additional
urinary tract anomalies included ureteropelvic junction
stenosis, renal collecting system anomalies (duplication,
renal dysplasia, or ureterocele), bladder exstrophy, and
neurogenic bladder. Children with recurrent UTI were also
stratified into a reinfection or relapse group. Receipt of
surgical intervention including endoscopic injection of
dextranomer hyaluronic acid or antireflux open surgery was
also evaluated.
A UTI was defined in this study as a single pathogen with
adequate colony forming units (CFU)/mL cultured from a
urine specimen obtained from voiding urine (>
100,000 CFU/mL), catheterized urine (> 10,000 CFU/mL),
or suprapubic puncture (> 1000 CFU/mL).8 Recurrent UTI
was defined as significant bacteriuria in children with fever
or dysuria during a 12-month follow-up period. Reinfection
was defined as a recurrent UTI with a new bacterial isolate
and relapse was defined as a recurrent UTI with the same
bacterial isolate as the primary isolate.
E. coli is the most common cause of community-acquired
UTI in children. In this study, children with UTI due to E.
coli were divided into a first episode group or a recurrent
episode group. Sensitivity of isolates to ampicillin, cefa-
zolin, gentamicin, amikacin, trimetho-
primesulfamethoxazole, cefotaxime or ceftazidime,
cefepime, ciprofloxacin, meropenem, and piper-
acillinetazobactam was tested in vitro using the disk
diffusion method according to the Clinical and Laboratory
Standards Institute standards.9
In our pilot study to evaluate the therapeutic effec-
tiveness of fosfomycin for preventing recurrent UTI, we
prospectively recruited six children with VUR and recurrent
UTI. Patients with UTI due to Enterobacteriaceae species
were administered fosfomycin 100e200 mg/kg/d every 8
hours for 7e10 days plus amikicin 15 mg/kg/d every 12
hours for 5 days. Patients with UTIs caused by Pseudomonas
aeruginosa were given fosfomycin 100e200 mg/kg/d every
8 hours for 7e10 days plus ceftazidime 100e150 mg/kg/
d every 8 hours for 7e10 days.
Statistical analysis
Ordinal variables are expressed as means  standard de-
viation (or median, range) and were compared between
Treatment of recurrent UTI in children 719groups using the ManneWhitney U test. Categorical vari-
ables, expressed as percentages, were analyzed using the
two-tailed Yates correction of contingency (when the ex-
pected value was > 5 with a 2  2 table) or the Pearson’s
Chi-square test. Kendall’s t-c (when there was a rectan-
gular table) was used for tests of trend. A p value < 0.05
was considered to represent statistical significance. All
analyses were performed using the statistical package SPSS
for Windows (version 20; SPSS Inc., Chicago, IL, USA).
Results
During the 10-year study period, a total of 129 children with
VUR developed UTIs; 68 (52.7%) had recurrent UTIs. The
rate of recurrence was 52.7%. VUR in each patient was
diagnosed after the first UTI. There were no significant
differences in age at diagnosis of the first UTI, gender,
reflux laterality, receipt of operation, or severity of reflux
grade between the recurrent and nonrecurrent UTI groups.
Underlying urinary tract anomalies were found in 21 (30.9%)
patients in the recurrent group and in eight (13.1%) patients
in the nonrecurrent group. Children with additional urinary
tract anomalies were at greater risk of recurrent UTI than
children without said anomalies (p Z 0.028; Table 1).
A total of 148 E. coli isolates were obtained from these
patients. The rates of antimicrobial susceptibility to some
antimicrobial agents empirically used as first-line treat-
ment, such as cefazolin, gentamicin, and cefotaxime were
markedly lower in patients with recurrent infection than in
those with nonrecurrent infection (Fig. 1). Rates of sensi-
tivity to cefazolin (p < 0.001) and cefotaxime (p < 0.001)
were significantly lower when used in patients with recur-
rent UTIs. Isolates remained highly susceptible to amikacin,
cefepime, ciprofloxacin, meropenem, and piper-
acillinetazobactam in both groups.
Of the 68 children in the recurrent group, 44 (64.7%)
developed reinfection, and 36 of them required surgicalTable 1 Characteristics of the children with UTI and VUR
Variable Recurrent UTI
n (%)
Age of first UTI (y) 2.38  3.15
Sex Male 35 (51.5)
Female 33 (48.5)
VUR Bilateral 35 (51.5)
Unilateral 33 (48.5)
VUR grade Grade 1 1 (1.5)
Grade 2 5 (7.4)
Grade 3 22 (32.4)
Grade 4 24 (35.3)
Grade 5 16 (23.5)
Surgical correction Yes 55 (80.9)
No 13 (19.1)
Additional urinary tract anomalies Yes 21 (30.9)
No 47 (69.1)
a ManneWhitney U test.
b Yates’s correction of contingency.
c Pearson Chi-square test.
UTI Z urinary tract infection; VUR Z vesicoureteral reflux.correction. The majority (n Z 33, 91.7%) did not develop
further episodes of UTI after surgical correction. The other
24 (35.3%) children in the recurrent group had relapsing
UTI, and 18 (75.0%) required surgical correction. Of those
patients, 13 (72.2%) relapsed after surgery. A total of 45
isolates of uropathogens were collected from the 24 chil-
dren with relapsing UTI. E. coli (53.3%) was the most
commonly isolated uropathogen. Non-E. coli isolates
included Klebsiella pneumoniae (15.6%), P. aeruginosa
(11.1%), Proteus mirabilis (6.7%), Alcaligenes xylosoxidans
(4.4%), Citrobacter freundii (2.2%), Klebsiella oxytoca
(2.2%), Morganella morganii, and Serratia marcescens
(2.2%; Table 2).
In the pilot study, six children with recurrent UTI due to
a single uropathogen were prospectively enrolled to receive
combination therapy comprising fosfomycin plus amikacin
or ceftazidime (Patients AeF). During the follow-up period,
one patient (Patient F) did not show evidence of further UTI
and four patients (Patient B, C, D, and E) had recurrent
episodes of UTI due to different uropathogens. One patient
(Patient A), however, had a recurrent episode due to the
same pathogen after combination therapy (Table 3).
Discussion
We found that children with reinfection responded well to
surgical correction. The majority (91.7%) of children did not
have further episodes of UTI after surgery during the 12
months of follow-up. Surgical intervention for persistent
VUR or recurrent UTI, including both open and endoscopic
methods, can provide curative treatment for some pa-
tients.6 However, the recurrence rate after surgical
correction in patients with relapsing UTI due to a single
pathogen is as high as 75.0%. Urinary and ureteral catheters
as well as surgery-related damage to structures can lead to
biofilm formation, which is associated with a recurrent
single uropathogen. E. coli isolates from UTI have beengroup (n Z 68) Nonrecurrent UTI group (n Z 61) p
n (%)
2.35  2.66 0.240a
27 (44.3) 0.521b
34 (55.7)
35 (57.4) 0.620b
26 (42.6)
2 (3.3) 0.573c
6 (9.8)
26 (42.6)
16 (26.2)
11 (18.0)
55 (90.2) 0.216b
6 (9.8)
8 (13.1) 0.028b
53 (86.9)
Figure 1. Drug susceptibility of Escherichia coli among the two groups. The antimicrobial agents cefazolin (72.1% vs. 32.4%,
p < 0.001) and cefotaxime (88.4% vs. 51.4%, p < 0.001) had significantly decreased susceptible rates of E. coli. TMP-
SMX Z trimethoprimesulfamethoxazole; UTI Z urinary tract infection.
Table 2 Urine culture results in the relapse group
(n Z 45)
Strain of urine culture n (%)
Escherichia coli 24 (53.3)
Klebsiella pneumoniae 7 (15.6)
Pseudomonas aeruginosa 5 (11.1)
Proteus mirabilis 3 (6.7)
Alcaligenes xylosoxidans 2 (4.4)
Citrobacter freundii 1 (2.2)
Klebsiella oxytoca 1 (2.2)
Morganella morganii 1 (2.2)
Serratia marcescens 1 (2.2)
Table 3 Uropathogens involved in and antimicrobial treatmen
reflux
No. Age
(y)
Sex Ep
1st 2nd 3rd 4th
A 0.2 M P. aeruginosac P. aeruginosa* P. aeruginosa* P. ae
B 0.2 M S. marcescensg S. marcescens* P. aeruginosa** P. ae
C 0.2 M E. colia P. aeruginosac P. aeruginosa* P. ae
D 0.1 M P. aeruginosa* E. cloacae* P. aeruginosa* P. ae
E 0.2 F E. colia E. coli-ESBL* E. colia E. co
F 0.2 F E. colia E. colia E. coli-ESBLg E. co
a 1st cephalosporin.
b 3rd cephalosporin.
c 4th cephalosporin.
d Ciprofloxacin.
e Amoxicillineclavulanate.
f Ampicillin.
g Meropenem.
* Fosfomycin for 7e10 days plus amikacin for 5 days.
** Fosfomycin plus ceftazidime for 7e10 days.
A. xylosoxidans Z Achromobacter xylosoxidans; Age Z age at
coli Z Escherichia coli; ESBL Z extended-spectrum b-lactamases
morganii Z Morganella morganii; M Z male; P. aeruginosa Z P
marcescens Z Serratia marcescens; T. beigelii Z Trichosporon beige
720 T.-H. Wu et al.shown to form biofilm in vitro.10 Biofilm represents a
structured community of bacterial cells embedded in a self-
produced polymeric matrix that adheres to natural or
artificial surfaces. The community is, therefore, protected
from antimicrobial agents and host immune defenses. A
recent review reported that the recurrence of UTI was
mainly caused by a relapse of the preceding E. coli infec-
tion, which supports evidence that E. coli can invade and
replicate within murine bladders, forming stable biofilm-
like intracellular reservoirs for recurrent UTI.11 It has
recently been suggested that biofilm plays an important
role in the pathogenesis or recurrence of UTI and persistent
colonization with the same strain of uropathogen.t for each recurrent episode in children with vesicoureteral
isode of UTI
5th 6th 7th
ruginosab P. aeruginosa** P. aeruginosa** P. aeruginosa**
ruginosa** P. aeruginosa** M. morganiif E. coli-ESBLe
ruginosa** P. aeruginosa** P. aeruginosa** K. pneumoniaed
ruginosa** P. mirabilise A. xylosoxidans** T. beigelii**
lib P. mirabilise d d
li* E. coli* d d
first episode of UTI; E. cloacae Z Enterobacter cloacae; E.
; F Z female; K. pneumoniae Z Klebsiella pneumoniae; M.
seudomonas aeruginosa; P. mirabilis Z Proteus mirabilis; S.
lii; UTI Z urinary tract infection.
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rent UTI in patients with VUR are becoming less effective.
Administration of first-generation cephalosporins, such as
cefazolin, as first-line empiric therapy can lead to treat-
ment failure because strains of many common causative
pathogens of UTI, particularly E. coli, are highly resistant.
Broad-spectrum antibiotics such as meropenem and piper-
acillinetazobactam are increasingly being used in children
with recurrent UTI. One systematic review reported that
fosfomycin, a very small hydrophilic compound with activ-
ity against several Gram-negative and Gram-positive aero-
bic bacteria, has a high level of antimicrobial activity
against extended-spectrum b-lactamase (ESBL)-producing
Enterobacteriaceae isolates with advanced resistance to
antimicrobial drugs.12 Moreover, it has been reported that
combinations of fosfomycin with other antimicrobial drugs
are successful against multidrug-resistant Gram-negative
pathogens and biofilm-related bacteria in vitro.13 In our
pilot study, we evaluated the effectiveness of combination
therapy comprising fosfomycin for 7e10 days plus amikacin
for 5 days to treat infections due to Enterobacteriaceae
species, and fosfomycin for 7e10 days plus ceftazidime for
7e10 days to treat infections due to P. aeruginosa in six
children with recurrent UTIs (Table 3). One of the six chil-
dren had a successful response and no further episodes of
infection were noted during 12 months of follow-up.
Recurrent episodes occurred in four of the six children;
however, in all four patients the uropathogens responsible
for the recurrent episodes differed from those in previous
episodes. Only one of the six children in the pilot study
failed to respond to combination therapy and had persis-
tent recurrent infections with the same uropathogen,
namely P. aeruginosa. Treatment failure in that child might
have been due to placement of a ureteral catheter to treat
underlying ureteropelvic junction stenosis. Combination
therapy comprising fosfomycin plus a second antimicrobial
drug was shown to be an effective therapeutic strategy;
however, further studies are needed to determine the ef-
ficacy of this treatment.
The most common uropathogen in primary and recurrent
UTIs is E. coli and cefazolin is the drug of choice for treating
such infections in children. In our previous study, we found
that 86.5% of E. coli isolates from children with a first
episode of community-acquired UTI were susceptible to
cefazolin alone.14 In another study conducted in Taiwan
during 2003e2010, the rates of susceptibility to cefazolin
among E. coli isolates obtained from children with
community-acquired UTI ranged from 62% to 73%.15 In the
current study, the sensitivity of E. coli to cefazolin in the
first episode group was 72.1%, but decreased to 32.4% in the
recurrent episode group. Younis et al16 demonstrated that
urine cultures of isolates from children with recurrent or
complicated UTIs are becoming increasingly resistant to
commonly used antibiotics such as trimetho-
primesulfamethoxazole or cephalexin.
In our study, the only significant predictor of recurrent
UTI was the presence of additional urinary tract anomalies
(30.9% vs. 13.1%, pZ 0.028), such as ureteropelvic junction
stenosis, renal collecting system anomalies (duplication,
renal dysplasia, ureterocele), or neurogenic bladder. One
possible reason for this finding is that some of our patients
were referred from local community hospitals with severeinfections or for early surgical intervention. Another
possible reason is that we included children with VUR and
urinary tract anomalies in our study. These children are
often exposed to other risk factors for recurrence such as
additional surgical procedures, the need for urinary cath-
eter placement, use of broad-spectrum antibiotics, and
longer hospital stay, variables that are well-known to in-
crease the rate of recurrence of UTI.
This study has some limitations, including its retro-
spective design and small sample size, which may have
limited our ability to identify differences between groups.
In addition, some important variables were not investigated
because of the retrospective nature of the study, including
the timing of diagnosing VUR, use of chemoprophylaxis, and
adequate imaging to evaluate the presence of renal scar-
ring. The definitions of reinfection and relapse utilized in
this study were purely clinical in nature and are limited by
the lack of clonal analysis. Finally, our pilot study on the
effectiveness of fosfomycin therapy was limited to only six
patients. Large-scale, prospective studies on fosfomycin
alone and in combination with other antimicrobials are
needed.
In conclusion, the rates of susceptibility of E. coli to
many commonly used antibiotic agents decreased in chil-
dren with VUR who were treated for recurrent UTI, espe-
cially in patients with additional urinary tract anomalies.
The empiric choice of cefazolin or cefotaxime alone for
recurrent UTI was usually ineffective. Surgical correction is
suggested for children with recurrent reinfection. Clinical
intervention comprising fosfomycin plus a second antimi-
crobial drug is a promising therapeutic and preventive
strategy for managing recurrent relapsing UTI in children
with VUR.Conflicts of interest
All contributing authors declare no conflicts of interest.Acknowledgments
We thank the Biostatistics Task Force of the Taichung Vet-
erans General Hospital, Taichung, Taiwan, R.O.C., and the
laboratory of the Taichung Veterans General Hospital for
help in the collection and analysis of specimens.References
1. Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary
tract infection in childhood: a meta-analysis. Pediatr Infect Dis
2008;27:302e8.
2. Duzova A, Ozen S. Vesicoureteral reflux in childhood. Saudi J
Kidney Dis Transplant 2003;14:290e5.
3. Shiraishi K, Yoshino K, Watanabe M, Matsuyama H, Tanikaze S.
Risk factors for breakthrough infection in children with primary
vesicoureteral reflux. J Urol 2010;183:1527e31.
4. Park S, Han JY, Kim KS. Risk factors for recurrent urinary tract
infection in infants with vesicoureteral reflux during prophy-
lactic treatment: effect of delayed contrast passage on voiding
cystourethrogram. Urology 2011;78:170e3.
722 T.-H. Wu et al.5. Jang HC, Park YJ, Park JS. Predicting factors of breakthrough
infection in children with primary vesicoureteral reflux. Yonsei
Med J 2012;53:748e52.
6. Peters CA, Skoog SJ, Arant Jr BS, Copp HL, Elder JS, Hudson RG,
et al. Summary of the AUA Guideline on Management of Pri-
mary Vesicoureteral Reflux in Children. J Urol 2010;184:
1134e44.
7. Elder JS, Peters CA, Arant Jr BS, Ewalt DH, Hawtrey CE,
Hurwitz RS, et al. Pediatric Vesicoureteral Reflux Guidelines
Panel summary report on the management of primary ves-
icoureteral reflux in children. J Urol 1997;157:1846e51.
8. Subcommittee on Urinary Tract Infection, Steering Committee
on Quality Improvement and Management, Roberts KB. Urinary
tract infection: clinical practice guideline for the diagnosis and
management of the initial UTI in febrile infants and children 2
to 24 months. Pediatrics 2011;128:595e610.
9. Clinical and Laboratory Standards Institute (CLSI). Perfor-
mance standards for antimicrobial susceptibility testing; 21st
informational supplement (CLSI document M100-S21). Wayne,
PA: Clinical and Laboratory Standards Institute; 2011.
10. Salo J, Sevander JJ, Tapiainen T, Ika¨heimo I, Pokka T,
Koskela M, et al. Biofilm formation by Escherichia coli isolated
from patients with urinary tract infections. Clin Nephrol 2009;
71:501e7.11. Ejrnæs K. Bacterial characteristics of importance for recurrent
urinary tract infections caused by Escherichia coli. Dan Mel
Bull 2011;58:B4187.
12. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE.
Fosfomycin for the treatment of multidrug-resistant, including
extended-spectrum beta-lactamase producing, Enter-
obacteriaceae infections: a systematic review. Lancet Infect
Dis 2010;10:43e50.
13. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME.
Clinical significance of the pharmacokinetic and pharmacody-
namic characteristics of fosfomycin for the treatment of pa-
tients with systemic infections. Int J Antimicrob Agents 2009;
34:506e15.
14. Lu KC, Chen PY, Huang FL, Yu HW, Kao CH, Fu LS, et al. Is
combination antimicrobial therapy required for urinary tract
infection in children? J Microbiol Immunol Infect 2003;36:
56e60.
15. Chen PC, Chang LY, Lu CY, Shao PL, Tsai IJ, Tsau YK, et al. Drug
susceptibility and treatment response of common urinary tract
infection pathogens in children. J Microbiol Immunol Infect
2014;47:478e83.
16. Younis N, Quol K, Al-Momani T, Al-Awaisheh F, Al-Kayed D.
Antibiotic resistance in children with recurrent or complicated
urinary tract infection. JNMA J Nepal Med Assoc 2009;48:14e9.
